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suggested as a way to incorporate uncertainty in the measurement of societal value
when setting the price of a new pharmaceutical. An alternative approach would be
may be to define one WTP threshold and then accept different levels of risk or a
different probability of being cost-effective at that threshold. For example innova-
tive products, cancer drugs and drugs for orphan diseases could be assessed with a
more flexible approach based on the system already in place. For example we may
be willing to accept only a 20% probability that the medicine is cost-effective at
£30,000/QALY. In theory, where there is greater uncertainty, the ICER could be any
value higher than 30K but at least there is a chance that the treatment is ‘cost-
effective’ for a proportion of patients. Similarly in disease areas where there is low
unmet need we could set the barrier higher and these medicines should have a
probability greater than 80% of being cost-effective at that threshold. So we have
one set of goalposts, if you shoot from the penalty spot you have to score but from
the half way line we can accept a few misses. CONCLUSION As a society we can
remain consistent in what we are willing to pay for a unit of health benefit. For
treatments where there is a high unmet need and an added benefit is perceived we
can afford to be more risky.
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OBJECTIVES: There are many thresholds for the value of a Quality-adjusted Life-
Year (QALY), varying between countries and jurisdictions, without however clear
evidence of the valuation process. The objective of this study was to systematically
review the literature for the evidence on the monetary valuation of a QALY.
METHODS: OVID MEDLINE® was independently searched for 1996-2011 by two
reviewers using the keywords [QALY or (Quality and Adjusted and Life and Years)]
and [Monetary and (Valuation or Value or (Value estimation) or (Value determina-
tion)]. Discrepancies in inclusion and data extraction were handled through agree-
ment. Included articles had to have applied a technique to determine the monetary
value of a QALY, either on patients, the public, both, or through other statistical
means. RESULTS: From 174 articles yielded by the review, 6 met the criteria, 4 were
European studies (Denmark, The Netherlands, the UK and Spain), and 1 from each
the USA and China. None of them targeted only patients for the valuation, 4 tar-
geted the general public, 2 studies focused on both. Three studies targeted a spe-
cific disease while 3 did not limit to any condition. Willingness-to-pay technique
was the most common valuation method (5/6) and QALYs were determined with
various direct or indirect elicitation measures. The average value for a QALY varied
from the equivalent of less than USD$5,000 to more than USD$100,000. While some
authors stated that preference valuation can lead to meaningful QALY values, the
majority agreed on the large variability of the results depending on many factors
such as income level, age, gender or disease condition and method of elicitation.
CONCLUSIONS: The literature on monetary valuation of a QALY is very limited,
and the range of reported values is very wide and can be differently impacted by the
survey tools used and by the characteristics of the population of interest.
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OBJECTIVES: Translational Research (TR) comprises activities aiming at the gener-
ation of biomedical knowledge, its transfer into clinical practice, and the take-up of
research questions in biomedical research. It is described as a non-unidirectional
process with mutual interexchange between different development stages. Health
Technology Assessment (HTA) is predominantly located in later phases of the
translational process where implementation, diffusion and dissemination of a
technology are focused. METHODS: Within the ELSA-GEN research collaboration,
institutional and social aspects of TR in genomic medicine were investigated (TRi-
Gen). We performed literature search and expert interviews to build a concept that
captures the potential feed-back loops HTA is involved in, and the characteristics
of interactions with actors in TR. RESULTS: Traditionally, HTA is applied on a
‘societal level’ and aims at public and clinical decision-makers. But it can also be
performed on a ‘project level’ to contribute in early phases of development by
evaluating premature technologies. In that context, interactions of HTA with man-
ufacturers, clinicians and, to a less extent, (basic) researchers become relevant.
Interactions are facilitated and shaped by specific organizational and institutional
structures. These ‘modes of interaction’ include approval and reimbursement reg-
ulations, funding structures, stakeholder involvement in the HTA process, and
prioritization of assessment topics. Formal prerequisites are not fulfilled between
all TR players and phases. Our analysis indicates that where they are not in place,
the full potential of HTA for the generation and translation of evidence in TR is not
met. Feed-back of HTA results regarding evidence gaps into the research agenda
could be strengthened. CONCLUSION: HTA can be regarded not only as a tool to
promote successful TR, but also as an additional actor that influences the transla-
tion of a technology in different stages. Organizational and institutional structures
need to be considered to foster its impact on the translation process.
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Attaining good patient health outcomes (HO) is the underlying purpose of any
health care intervention, including drug therapy. The measurement of HO is the
basis for evaluating the quality of health services, and a key element in determin-
ing the value of health interventions. Along with effectiveness, long term safety is
an important component of HO of new authorised human medicines. The explicit
assessment of the sustained benefit-risk trade-off of new authorised products
must be undertaken to ensure that unintended harmful consequences are not
offsetting the intended clinical benefits. Spontaneous reporting schemes provide a
means of continuous surveillance of medicines that is important for raising early
signals of safety concerns, but ad-hoc post-authorisation safety studies (PASS) may
be necessary to evaluate the safety of medicines more accurately. The European
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) is
an initiative led by the European Medicines Agency aimed at further strengthening
post- authorisation medicines research in Europe by facilitating the conduct of
multi-centre, independent PASS focusing on safety and on benefit/risk. Specifi-
cally, ENCePP provides a unique point of access for all involved stakeholders seek-
ing collaboration for the commissioning or the conduct of PASS. This is achieved by
offering access to available expertise and research experience in the fields of phar-
macoepidemiology and pharmacovigilance across Europe brought together into a
functioning network of excellence. It is anticipated that ENCePP will add to knowl-
edge and the EU capacity to conduct PASS studies in the light of shared methodol-
ogies and expertise. In doing so, ENCePP can serve as a bridge between medicines
regulation and HO research in supporting risk/benefit management planning to
minimise adverse events and maximise the benefit of marketed medicines.
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OBJECTIVES: Russia has a severe access to medicines problem. Of the 142 million
people in Russia, only 20 million are eligible for outpatient medicines coverage as
part of the Supplementary Medicines Cover (DLO) programme. More than half of
the eligible opt-out for cash. The current government’s goal is to eventually estab-
lish universal outpatient medicines coverage. This study explores pharmaceutical
policy options for Russia to improve efficiency and access to medicines. We employ
a conceptual framework to explain Russia’s priorities and the weighing of each
health policy component in developing policy approaches. Based on Russia’s par-
ticular policy needs, as well as economic environment and market structure, we
provide policy options anchored in lessons from the European Union and the
United States. Overall, Russia requires more efficient pricing policies to increase
coverage and access to medicines. METHODS: Our findings suggest that, although
generic market shares are high, there is room for lower generic prices. In order to
address this inefficiency, we propose the adoption of tenders for high-selling off-
patent molecules, and free pricing for molecules with sufficient market competi-
tion. The combination of external price referencing and tenders at the wholesaler
level for in-patent markets is confusing, and in order to make originator pricing
more efficient, we suggest health technology assessment. As universal coverage is
a priority, additional funding will be required with potential sources coming from
co-payments or abolishing the possibility of opting-out of the DLO for cash. Im-
proving efficiency in the. RESULTS: Russian pharmaceutical market will make an
additional monetary unit to be invested in medicines rather than somewhere else
in the policy environment have a positive effect on social welfare. CONCLUSIONS:
Russia can achieve greater efficiency and lower prices in its pharmaceutical mar-
ket, which would contribute to reaching the goal of universal outpatient medicines
coverage.
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OBJECTIVES: Understand the impact of AMNOG on pharmaceutical pricing trends.
METHODS: The reforms implemented by AMNOG were reviewed by analysing re-
cent changes in German healthcare system. A basket of five branded products was
chosen to analyse pricing trends for past four quarters (Q3 2010, Q4 2010, Q1 2011,
Q2 2011). Quarterly increase or decrease in prices were compared for all five drugs.
RESULTS: AMNOG introduced major changes in German healthcare system. Tra-
ditionally Germany was one of the highest priced pharmaceutical markets in Eu-
rope, with significant price inflation. However, since the implementation of AM-
NOG, there has not been any price inflation for the selected five branded products.
Our analysis shows that prices have either declined or stayed steady during past
four quarters. Some products such as Aranesp saw significant price decreases
(5-9% per quarter), driven by AMNOG and by launch of cheaper biosimilar products.
Other products show deflation of 0.6-1% per quarter. CONCLUSIONS: Pharmaceu-
tical pricing landscape in Germany has significantly altered since the implemen-
tation of AMNOG. Newer products would need to demonstrate improvement in
comparative efficacy to command premium launch price or increase in price.
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